Quantitative PCR for parasitemia monitoring and preemptive therapy in patients with Chagas disease and autoimmune rheumatic disorders undergoing biologic treatment: a case series

Patients with chronic Chagas disease (CD) and autoimmune rheumatic disorders (ARD) receiving immunosuppressive therapy are at risk for CD reactivation (CDR). This study monitored parasitemia over 9-121 months in six patients with CD and ARD using conventional and quantitative PCR and parasitology. Five patients showed parasitemia; two had elevated levels of parEq/mL (49-458.7). One patient received benznidazole with a marked decrease in parasitemia; in the other, treatment was discontinued after 12 days due to toxicity. No CDR occurred. These findings support the need for qPCR standardization for preemptive therapy and suggest that benznidazole may prevent CDR in patients with high parasitemia.

Authors

Institutions

Publication Details

Journal
Revista da Sociedade Brasileira de Medicina Tropical
Published
2025-01-01
DOI
https://doi.org/10.1590/0037-8682-0419-2024
Primary Topic
Trypanosoma species research and implications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quantitative PCR for parasitemia monitoring and preemptive therapy in patients with Chagas disease and autoimmune rheumatic disorders undergoing biologic treatment: a case series

Karina Rossi Bonfiglioli, Vera Lúcia Teixeira de Freitas, Hermes Ryoiti Higashino, Érika Yoshie Shimoda Nakanishi et al.
Revista da Sociedade Brasileira de Medicina Tropical
Trypanosoma species research and implications
article

Quantitative PCR for parasitemia monitoring and preemptive therapy in patients with Chagas disease and autoimmune rheumatic disorders undergoing biologic treatment: a case series

Karina Rossi Bonfiglioli, Vera Lúcia Teixeira de Freitas, Hermes Ryoiti Higashino, Érika Yoshie Shimoda Nakanishi, Adriana Coracini Tonácio, Maria Aparecida Shikanai‐Yasuda, Noêmia Barbosa Carvalho, Nádia Emi Aikawa, Lucas T. Vieira, Rita Cristina Bezerra
article en

Abstract

Patients with chronic Chagas disease (CD) and autoimmune rheumatic disorders (ARD) receiving immunosuppressive therapy are at risk for CD reactivation (CDR). This study monitored parasitemia over 9-121 months in six patients with CD and ARD using conventional and quantitative PCR and parasitology. Five patients showed parasitemia; two had elevated levels of parEq/mL (49-458.7). One patient received benznidazole with a marked decrease in parasitemia; in the other, treatment was discontinued after 12 days due to toxicity. No CDR occurred. These findings support the need for qPCR standardization for preemptive therapy and suggest that benznidazole may prevent CDR in patients with high parasitemia.

Revista da Sociedade Brasileira de Medicina TropicalVol. 58
Universidade de São Paulo (BR), Universidade Brasil (BR)
Fundação de Amparo à Pesquisa do Estado de São Paulo, Universidade de São Paulo
Openalex Percentile: Top 82%
Trypanosoma species research and implications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.